Company profile
Respiratorius AB (publ) company profile
Respiratorius AB develops new effective drugs for cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The company also runs a project within PET imaging with application in cardiovascular diagnostics. The company is currently conducting clinical development of a drug project (VAL-001), for the treatment of Diffust Large Cell B cell lymphoma. In COPD and asthma, Respiratorius has focused on a new class of patent-pending drug substances, which compared to existing therapies have a superior ability to relax the small airways. The substances, which utilize a new mechanism of action, have been developed via ex-vivo experiments on human lung tissue..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Contact email
- [email protected]
- Phone number
- +46 70 922 41 40
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Revenue range
- $100K+
- Founded
- 1999-01-01
Headquarters
- Headquarters
- Lund, Skane Lan, Sweden
- Postal code
- 223 81
- Country code
- SE
- Continent
- Europe